Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

Biotechnology

Health & Wellness

Health Care

Pharmaceutical

Amolyt Pharma

Thierry Abribat

Niccole Larsen, PhD

michel ovize

Blandine WEISS

Taha Ould Rouis, MD

Caroline Robo (Fesquet)

Patrick Loustau

Michael Culler

Lou Arcudi

Laetitia Ouafki

Héloïse Boullet

Guillaume Ravel, PharmD, PhD, DABT

Delphine Martinez

Damien Aumaille

Clémentine Chalmey

Aurélie MILLERAT

The Leadership Team at Amolyt Pharma is responsible for setting the strategic vision, overseeing financial planning, directing scientific research, and managing business development to advance the company's mission of developing peptides for rare endocrine and metabolic disorders.

Leadership Team

Clinical Management Team

CMC Team

Leadership Team

About

Team members

Other teams at Amolyt Pharma

Clinical Management Team

CMC Team